Brian Andrew Van Tine
YOU?
Author Swipe
View article: 1311 Targeting TGF-β RI signaling with the novel vactosertib: preliminary antitumor activity in a phase 1 study in patients with recurrent, refractory, and progressive osteosarcoma
1311 Targeting TGF-β RI signaling with the novel vactosertib: preliminary antitumor activity in a phase 1 study in patients with recurrent, refractory, and progressive osteosarcoma Open
View article: 320 Integrated efficacy and safety analysis of letetresgene autoleucel, a T-cell receptor T-cell therapy, across clinical trials of patients with synovial sarcoma and myxoid/round cell liposarcoma
320 Integrated efficacy and safety analysis of letetresgene autoleucel, a T-cell receptor T-cell therapy, across clinical trials of patients with synovial sarcoma and myxoid/round cell liposarcoma Open
View article: Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies Open
IMCnyeso, an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) bispecific (New York esophageal squamous cell carcinoma [NY-ESO]×CD3) T cell engager, targets an NY-ESO-1/L-antigen family member-1 isoform A (LAGE-1A) pepti…
View article: The Effect of Food on the Pharmacokinetics of Unesbulin in Patients with Advanced Leiomyosarcoma
The Effect of Food on the Pharmacokinetics of Unesbulin in Patients with Advanced Leiomyosarcoma Open
Unesbulin is an orally bioavailable small molecule binding to the colchicine-binding site of tubulin and impeding tubulin polymerization and microtubule formation. It has been investigated as a monotherapy and in combination with other med…
View article: Signaling pathways and targeted therapies in Ewing sarcoma
Signaling pathways and targeted therapies in Ewing sarcoma Open
Ewing sarcoma, the second most prevalent malignant bone tumor with potential occurrence in soft tissues, exhibits a high level of aggressiveness, primarily afflicting children and adolescents. It is characterized by fusion proteins arising…
View article: Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial Open
View article: 54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1
54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1 Open
Afamitresgene autoleucel (afami-cel) is an autologous engineered T-cell receptor T-cell therapy targeting tumors expressing melanoma-associated antigen A4 (MAGE-A4). Cohort 1 of the phase 2 SPEARHEAD-1 trial showed a response rate of 38.6%…
View article: 58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment
58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment Open
In 2019, pexidartinib was US FDA-approsssved (800 mg/day TDD) for TGCT patients with severe morbidity or functional limitations not amenable to improvement with surgery. Per label, dose modifications are recommended in certain scenarios, y…
View article: 1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma Open
View article: Biphenotypic Sinonasal Sarcoma with a Novel PAX7::PPARGC1 Fusion: Expanding the Spectrum of Gene Fusions Beyond the PAX3 Gene
Biphenotypic Sinonasal Sarcoma with a Novel PAX7::PPARGC1 Fusion: Expanding the Spectrum of Gene Fusions Beyond the PAX3 Gene Open
View article: Data from Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis
Data from Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis Open
Taspase1, the mixed lineage leukemia and TFIIAα-β cleaving protease, enables cell proliferation and permits oncogenic initiation. Here, we show its critical role in cancer maintenance and thus offer a new anticancer target. Taspase1 is ove…
View article: Data from A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth
Data from A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth Open
The threonine endopeptidase Taspase1 has a critical role in cancer cell proliferation and apoptosis. In this study, we developed and evaluated small molecule inhibitors of Taspase1 as a new candidate class of therapeutic modalities. Geneti…
View article: Supplementary Methods, Figures 1-7, Tables 1-3 from A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth
Supplementary Methods, Figures 1-7, Tables 1-3 from A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth Open
PDF file - 782K
View article: Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness Open
View article: Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial
Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial Open
Background Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of oluta…
View article: Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism
Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism Open
View article: Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas Open
View article: Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma Open
Osteosarcoma is the most common pediatric and adult primary malignant bone cancer. Curative regimens target the folate pathway, downstream of serine metabolism, with high-dose methotrexate. Here, the rate-limiting enzyme in the biosynthesi…
View article: A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy Open
View article: ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY
ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY Open
BACKGROUND Isocitrate dehydrogenase mutations (mIDH1) are present in > 70% of patients with Grade II/III gliomas resulting in production and accumulation of (R)-2-hydroxyglutarate causing DNA hypermethylation and promoting tumorigenesis. F…
View article: Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma Open
ClinicalTrials.gov, NCT01343043 , Registered 27 April 2011.
View article: Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma Open
View article: The Metastatic Spine Disease Multidisciplinary Working Group Algorithms
The Metastatic Spine Disease Multidisciplinary Working Group Algorithms Open
View article: Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers
Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers Open
Many cancers lack functional expression of the enzyme argininosuccinate synthetase 1 (ASS1) that is necessary for synthesis of L-arginine. These cancers must import arginine for survival and growth, and this reliance can be targeted by arg…
View article: Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma Open
www.clinicaltrials.gov, NCT01343277.
View article: Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers Open
View article: Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials Open
View article: Amino Acid Uptake Measured by [<sup>18</sup>F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas
Amino Acid Uptake Measured by [<sup>18</sup>F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas Open
Rational: In a subset of cancers, arginine auxotrophy occurs due to the loss of expression of argininosuccinate synthetase 1 (ASS1). This loss of ASS1 expression makes cancers sensitive to arginine starvation that is induced by PEGy…
View article: Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience Open
Patients with RPS treated with peri-operative IMRT at our institution had excellent local control and low incidences of toxicity.
View article: Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect
Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect Open
Argininosuccinate Synthetase 1 deficiency induces dependence on extracellular arginine for continued cellular growth and survival. Arginine starvation inhibits the Warburg effect and diverts glucose into serine biosynthesis, while simultan…